Introduction {#Sec1}
============

The family Selaginellaceae Willk. includes the single genus *Selaginella* Beauv. *Selaginella* is a nearly worldwide genus of about 700 species, with 72 of them in China and more than 20 species used in traditional Chinese medicine \[[@CR1], [@CR2]\]. Several *Selaginella* species including *S. delicatula* (Desv. ex Poir.) Alston, *S. moellendorffii* Hieron., *S. nipponica* Franch. & Sav., *S. sanguinolenta* (L.) Spring, *S. stauntoniana* Spring, and *S. tamariscina* (P. Beauv.) Spring are used in promotion of blood circulation (Huoxue in Chinese) \[[@CR1]\]. Traditional Chinese medicines with the functions of "Huoxue" and/or "Huayu" (removing blood stasis) are claimed to be useful in antiplatelet therapies and the treatment of thrombotic diseases \[[@CR3], [@CR4]\]. Previously, a pyrrolidinoindoline alkaloid selaginellic acid with antiplatelet activity was found from the whole plant of *S. moellendorffii* \[[@CR5], [@CR6]\]. This result prompted us to further investigate the plant which led to the isolation of nine compounds (**1**--**9**, Fig. [1](#Fig1){ref-type="fig"}) including two new neolignans (**1** and **2**). Compounds **1**--**9**, as well as those (**10**--**18**) previously isolated from the plant \[[@CR5], [@CR7], [@CR8]\], were evaluated for antiplatelet activity. The structural elucidation of the new compounds and the bioassay results are reported.Fig. 1The chemical structures of **1**--**9** from *Selaginella moellendorffii*

Results and Discussion {#Sec2}
======================

The HRESIMS analysis of selaginellol (**1**) gave an \[M+Na\]^+^ ion at *m/z* 415.1729 appropriate for a molecular formula of C~21~H~28~O~7~ requiring eight sites of unsaturation. The IR absorption signals revealed the presence of hydroxy (3428 cm^−1^) and aromatic (1614, 1518, 1496, and 1461 cm^−1^) groups. The ^1^H NMR data of **1** (Table [1](#Tab1){ref-type="table"}) exhibited three methoxy groups \[*δ* ~H~ 3.82 (3H, s) and 3.70 (6H, s)\], and two 1,2,3,5-tetrasubstituted benzene rings \[*δ* ~H~ 6.30 (2H, s); 6.63 (d, *J* = 1.6 Hz) and 6.47 (d, *J* = 1.6 Hz)\]. The ^13^C NMR data of **1** (Table [1](#Tab1){ref-type="table"}) showed the signals for three methoxy groups (*δ* ~C~ 56.5 × 2 and 56.4), two phenyl rings, five methylenes including two oxygenated ones (*δ* ~C~ 65.9, 62.2, 37.9, 35.8, and 32.8), and one methine (*δ* ~C~ 45.4). According to above NMR signal characteristics \[[@CR8]\], compound **1** might be a neolignan.Table 1^1^H (600 MHz) and ^13^C (150 MHz) NMR data of **1** and **2** in CD~3~OD (*δ* in ppm, *J* in Hz)Position**12***δ* ~H~*δ* ~C~*δ* ~H~*δ* ~C~1132.9 (C)132.5 (C)2,66.30 (s)107.3 (CH)6.28 (s)107.0 (CH)3,5148.7 (C)148.6 (C)4134.2 (C)134.1 (C)73.00 (dd, 13.4, 5.7)\
2.88 (dd, 13.4, 9.4)37.9 (CH~2~)3.01 (dd, 14.0, 5.0)\
2.71 (dd, 14.0, 10.0)39.6 (CH~2~)83.42 (m)45.4 (CH)3.96 (m)42.7 (CH)93.76 (m)65.9 (CH~2~)3.76 (dd, 10.6, 4.8)\
3.67 (dd, 10.6, 7.9)67.1 (CH~2~)1′133.7 (C)140.4 (C)2′6.47 (d, 1.6)122.0 (CH)6.73 (d, 1.8)120.2 (CH)3′129.3 (C)138.5 (C)4′143.7 (C)143.5 (C)5′148.7 (C)153.2 (C)6′6.63 (d, 1.6)110.6 (CH)6.72 (d, 1.8)111.6 (CH)7′2.53 (t, 7.5)32.8 (CH~2~)2.64 (t, 7.6)33.1 (CH~2~)8′1.74 (m)35.8 (CH~2~)1.82 (m)35.7 (CH~2~)9′3.51 (t, 6.4)62.2 (CH~2~)3.57 (t, 6.2)62.2 (CH~2~)1″4.57 (d, 7.5)105.6 (CH)2″3.44 (m)75.9 (CH)3″3.39 (m)77.8 (CH)4″3.38 (m)71.1 (CH)5″3.11 (m)78.0 (CH)6″3.79 (overlapped)\
3.70 (overlapped)62.4 (CH~2~)3,5-OMe3.70 (s)56.5 (CH~3~)3.70 (s)56.5 (CH~3~)5′-OMe3.82 (s)56.4 (CH~3~)3.80 (s)56.3 (CH~3~)

The ^1^H--^1^H COSY correlations (Fig. [2](#Fig2){ref-type="fig"}) exhibited two partial structures from C-7 to C-9 and C-7′ to C-9′. Based on the HMBC correlations (Fig. [2](#Fig2){ref-type="fig"}) from H-2 and H-6 to C-4, H~2~-7 to C-2 and C-6, H-8 to C-1, H~2~-8′ to C-1′, H~2~-7′ to C-2′ and C-6′, H-2′ and H-6′ to C-4′, 3-OMe to C-3, 5-OMe to C-5, and 5′-OMe to C-5′, two phenylpropanoid moieties, namely 4-(3-hydroxypropyl)-2,6-dimethoxyphenol and 4-(3-hydroxypropyl)-2-methoxyphenol, were confirmed. The two fragments were linked through C-8-C-3′ by the HMBC correlations from H~2~-7 and H~2~-9 to C-3′ as well as H-8 to C-2′ and H-2′ to C-8. Therefore, the relative configuration of **1** was elucidated as 3,5,5′-trimethoxy-8,3′-neoligna-4,4′,9,9′-tetraol. The absolute configuration of selaginellol (**1**) was elucidated as (8*R*)-3,5,5′-trimethoxy-8,3′-neoligna-4,4′,9,9′-tetraol by comparing its electronic circular dichroism (ECD) spectrum \[Δ*ε* −0.12 (273)\] with that of a known analogue secodihydrodehydrodiconiferyl alcohol tetraacetate \[[@CR9]\].Fig. 2Key 2D NMR correlations of **1** and **2**

According to the HREIMS ion at *m/z* 554.2365 \[M\]^+^ (calcd for C~27~H~38~O~12~, 554.2363), the molecular formula of compound **2** was determined as C~27~H~38~O~12~ with nine degrees of unsaturation. The IR absorption signals showed the presence of hydroxy (3425 cm^−1^) and aromatic (1614, 1518, and 1461 cm^−1^) groups. The NMR data (Table [1](#Tab1){ref-type="table"}) of **2** were very similar to those of **1**, except that more signals for a β-glucopyranosyl moiety \[*δ* ~H~ 4.57 (d, *J* = 7.5 Hz); *δ* ~C~ 105.6, 75.9, 77.8, 71.1, 78.0, and 62.4\] were observed. As demonstrated in the ^1^H--^1^H COSY, HMBC and ROESY correlations (Fig. [2](#Fig2){ref-type="fig"}), compound **2** was determined to be the β-glucopyranoside of selaginellol (**1**). The HMBC correlation from H-1″ to C-4′ indicated that the β-glucopyranosyl part was located at C-4′. According to our previously acidic hydrolysis of rel-(7*R*,8*S*)-3,3′,5-trimethoxy-4′,7-epoxy-8,5′-neoligna-4,9,9′-triol 4-*O*-β-[d]{.smallcaps}-glucopyranoside (**11**) \[[@CR8]\], the sugar in the plant is [d]{.smallcaps}-glucose. The absolute configuration of the aglycone was elucidated to be the same as that of selaginellol (**1**) by comparison of its ECD spectrum \[Δ*ε* −0.37 (273)\] with that of **1**. Therefore, compound **2** is selaginellol 4′-*O*-β-[d]{.smallcaps}-glucopyranoside.

The known compounds were determined as (−)-syringaresinol (**3**) \[[@CR10]\], (−)-lariciresinol (**4**) \[[@CR11]\], 7*S*,7′*S*,8*R*,8′*R*-icariol A~2~ (**5**) \[[@CR12]\], lyoniside (**6**) \[[@CR13]\], (−)-8,8′-bisdihydrosiringenin (**7**) \[[@CR14]\], (7*S*,8*R*)-3,3′,5-trimethoxy-4′,7-epoxy-8,5′-neoligna-4,9,9′-triol (**8**) \[[@CR8]\], and dihydrosinapyl alcohol (**9**) \[[@CR15]\], by comparing their NMR data (for all known compounds) and optical rotation values (for the neolignans) with those reported in the literature.

All of these compounds (**1**--**9**), along with those previously isolated from the plant, including (7*S*,8*R*)-4,9-dihydroxy-3,3′,5-trimethoxy-4′,7-epoxy-8,5′-neolignan-9′-oic acid methyl ester (**10**) \[[@CR8]\], rel-(7*R*,8*S*)-3,3′,5-trimethoxy-4′,7-epoxy-8,5′-neoligna-4,9,9′-triol 4-*O*-β-[d]{.smallcaps}-glucopyranoside (**11**) \[[@CR8]\], rel-(7*R*,8*S*)-3,3′,5-trimethoxy-4′,7-epoxy-8,5′-neoligna-4,9,9′-triol 9-*O*-β-[d]{.smallcaps}-glucopyranoside (**12**) \[[@CR8]\], 3,3′,5-trimethoxy-4′,7-epoxy-8,5′-neolign-7-ene-4,9,9′-triol 9-*O*-β-[d]{.smallcaps}-glucopyranoside (**13**) \[[@CR8]\], 5-carboxymethyl-7,4′-dihydroxyflavanone 7-*O*-β-[d]{.smallcaps}-glucopyranoside (**14**) \[[@CR7]\], *N*-selaginelloyl-[l]{.smallcaps}-phenylalanine (**15**) \[[@CR5]\], paucine 3′-*O*-β-[d]{.smallcaps}-glucopyranoside (**16**) \[[@CR8]\], paucine (**17**) \[[@CR8]\], and *N* ^1^-*cis*-*p*-coumaroylagmatine (**18**) \[[@CR8]\], were evaluated for the inhibitory activity against platelet aggregation induced by ADP or collagen. As shown in Table [2](#Tab2){ref-type="table"}, compounds **8**, **11**, **12**, **14**, and **16** showed potential inhibitory activity against ADP-induced platelet aggregation with IC~50~ values of 80.84, 35.76, 42.47, 27.70, and 59.19 µM, respectively, as compared with the positive control tirofiban (IC~50~ = 25.32 µM). Compounds **8**, **11**, **12**, and **14** also showed the activity against collagen-induced platelet aggregation with IC~50~ values of 146.70, 31.17, 24.57, and 26.25 µM, respectively, as compared with the positive control tirofiban (IC~50~ = 148.20 µM). The dihydrobenzofuran neolignans (**8**, **11**, and **12**) are more potent than the benzofuran neolignan (**13**) and other types of neolignans (**1**--**7**). Glucosidation of the dihydrobenzofuran neolignans (**11** and **12**) is helpful for the activity as compared the bioassay result of **11** and **12** with that of **8**.Table 2The effect of compounds on rabbit platelet aggregation induced by ADP (10 μM) or collagen (2.5 μg/mL)CompoundADP (IC~50~ µM)Collagen (IC~50~ µM)**8**80.84146.70**11**35.7631.17**12**42.4724.57**14**27.7026.25**16**59.19\>200Tirofiban (positive control)25.32148.20

Experimental Section {#Sec3}
====================

General Experimental Procedures {#Sec4}
-------------------------------

Optical rotations were recorded using a JASCO P-1020 Polarimeter (Jasco Corp., Tokyo, Japan). UV spectra were taken on a Shimadzu UV-2401 PC spectrophotometer (Shimadzu, Kyoto, Japan). ECD spectra were recorded on a Chirascan CD spectrometer (Applied Photophysics Ltd., Leatherhead, UK). IR spectra were measured on a Bruker Tensor 27 FTIR Spectrometer (Bruker Corp., Ettlingen, Germany) with KBr disks. ^1^H and ^13^C NMR spectra were collected on Bruker Avance 400, DRX-500 or Avance III-600 spectrometers (Bruker Bio-Spin GmbH, Rheinstetten, Germany) with TMS as an internal standard. ESIMS and HRESIMS analyses were carried out on an API QSTAR Pulsar 1 spectrometer (Applied Biosystems/MDS Sciex, Foster City, CA, USA). HREIMS were carried out on a Waters AutoSpec Premier p776 spectrometer (Waters, Millford, MA, USA). Silica gel G (80--100 and 300--400 mesh, Qingdao Meigao Chemical Co., Ltd., Qingdao, China), C~18~ silica gel (40--75 μm, Fuji Silysia Chemical Ltd., Aichi, Japan), Sephadex LH-20 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), and D~101~ macroporous resin (Qingdao Marine Chemical Ltd., Qingdao, China) were used for column chromatography, and silica gel GF~254~ (Qingdao Meigao Chemical Co., Ltd.) was used for preparative TLC as precoated plates. TLC spots were visualized under UV light at 254 nm and by dipping into 5 % H~2~SO~4~ in alcohol followed by heating. Semipreparative HPLC was performed on an Agilent 1200 series pump (Agilent Technologies, Santa Clara, USA) equipped with a diode array detector and an Agilent Zorbax SB-C~18~ column (5.0 μm, *ϕ* 9.4 × 250 mm).

Plant Material {#Sec5}
--------------

The whole plant of *S.* *moellendorffii* was collected from Jingxi County of Guangxi Zhuang Autonomous Region in 2008. A voucher specimen (No. JX0801) was identified by one of the authors (Chun-Lin Long) and deposited at the Key Laboratory of Economic Plants and Biotechnology, Kunming Institute of Botany, Chinese Academy of Sciences.

Extraction and Isolation {#Sec6}
------------------------

The air-dried, powdered *S. moellendorffii* plants (15 kg) were exhaustively extracted with MeOH (45 L × 3) at 60 °C. The solvent was removed to give a residue (0.89 kg). The crude extract was subjected to chromatography on a D~101~ macroporous resin column eluted successively with H~2~O, 35 % EtOH, and 95 % EtOH to give three portions (I--III), respectively. Portion II (398 g) was subjected to column chromatography (silica gel G; CHCl~3~/MeOH, 1:0 → 0:1, v/v) to yield six fractions (A--F). Fr. A was subjected to column chromatography (silica gel G; petroleum ether/EtOAc, 15:1 → 0:1, v/v) to yield four fractions (A1--A4). Fr. A1 was purified by column chromatography (silica gel G; CHCl~3~-acetone, 15:1, v/v) to obtain **9**. Fr. A2 was chromatographed on a Sephadex LH--20 column (MeOH) to give subfractions A2--1 and A2--2. Subfraction A2--1 was subjected to chromatography on a silica gel G column (CHCl~3~-acetone, 20:1, v/v) and then further purified by semi-preparative HPLC (MeCN/H~2~O, 30:70, v/v) to yield **4** (14.9 mg, *t* ~R~ = 13.099 min). Subfraction A2-2 was purified by preparative TLC (CHCl~3~/MeOH, 10:1, v/v) to obtain **3** (24.6 mg). Fr. A3 was chromatographed over a C~18~ silica gel column (MeOH/H~2~O, 30:70, v/v), a Sephadex LH-20 column (MeOH), and a silica gel G column (CHCl~3~/MeOH/H~2~O, 50:1:0.25), and purified by semi-preparative HPLC (MeOH/H~2~O, 40:60, v/v) to obtain **5** (15.5 mg, *t* ~R~ = 5.864 min). Fr. A4 was chromatographed on a Sephadex LH-20 column (MeOH), a C~18~ silica gel (MeOH/H~2~O, 50:50, v/v), and a silica gel G column (CHCl~3~/MeOH, 60:1, v/v), and purified by semi-preparative HPLC (MeCN/H~2~O, 30:70, v/v) to yield **7** (2.0 mg, *t* ~R~ = 7.716 min), **8** (2.0 mg, *t* ~R~ = 8.917 min) and **1** (4.0 mg, *t* ~R~ = 13.652 min). Fr. D was chromatographed on a C~18~ silica gel column (MeOH/H~2~O, 30:70, v/v), a Sephadex LH-20 column (MeOH), and a silica gel G column (CHCl~3~/MeOH/H~2~O, 100:10:0.5, v/v), and purified by semi-preparative HPLC (MeOH/H~2~O, 40:60, v/v) to yield **2** (7.8 mg, *t* ~R~ = 12.138 min) and **6** (4.4 mg, *t* ~R~ = 18.734 min).

### Selaginellol (**1**) {#Sec7}

Pale yellow oil (MeOH); \[α\]~D~^24^ −50.4 (*c* 0.40, MeOH); UV (CH~3~OH) *λ* ~max~ (log *ε*) 280 (3.31), 228 (3.98) nm; ECD Δ*ε* (*c* 0.010, MeOH) −0.12 (273), −3.84 (214), +3.63 (197); IR (KBr) *v* ~max~ 3428, 1614, 1518, 1496, 1461, 1431, 1289, 1217, 1114 cm^−1^; ^1^H and ^13^C NMR data, see Table [1](#Tab1){ref-type="table"}; positive ion ESIMS *m/z* 415 \[M+Na\]^+^; positive ion HRESIMS *m/z* 415.1729 \[M+Na\]^+^ (calcd for C~21~H~28~O~7~Na^+^, 415.1727).

### Selaginellol 4′-*O*-β-[d]{.smallcaps}-glucopyranoside (**2**) {#Sec8}

Pale yellow solid (MeOH); \[α\]~D~^22^ −57.8 (*c* 0.26,MeOH); UV (CH~3~OH) *λ* ~max~ (log *ε*) 274 (3.80) nm; ECD Δ*ε* (*c* 0.011, MeOH) −0.37 (273), −6.17 (210), +3.20 (200); IR (KBr) *v* ~max~ 3425, 1615, 1518, 1461, 1428, 1325, 1216, 1113, 1071 cm^−1^; ^1^H and ^13^C NMR data, see Table [1](#Tab1){ref-type="table"}; positive ion ESIMS *m/z* 577 \[M+Na\]^+^; HREIMS *m/z* 554.2365 \[M\]^+^ (calcd for C~27~H~38~O~12~, 554.2363).

In Vitro Platelet Aggregation Assay {#Sec9}
-----------------------------------

In vitro platelet aggregation was conducted using the turbidimetric method with a minor modification \[[@CR16], [@CR17]\]. Briefly, blood was withdrawn from the carotid artery of New Zealand rabbits,and anticoagulated with 3.8 % sodium citrate (1:9 citrate/blood, v/v) and centrifuged for 15 min at 950 rpm to prepare platelet-rich plasma (PRP) or 10 min at 3000 rpm to obtain platelet-poor plasma (PPP). The platelet concentration was adjusted to 3 × 10^8^ platelets/mL. PRP in 270 μL was preincubated at 37 °C for 5 min in the cuvette with 20 μL of sample or vehicle (saline), and then platelet aggregation was induced by 10 μL ADP (10 μM) or collagen (2.5 μg/mL). The maximum platelet aggregation rate was determined within 5 min with continuous stirring at 37 °C using four-channel aggregometer (Beijing Steellex Science Instrument Company, China).

For each compound, five concentrations were chosen and a percentage inhibition-concentration curve was derived. From this curve the IC~50~ value was calculated as the concentration of inhibitor causing a 50 % inhibition of the aggregation using SPSS software.
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